Research Summary: Muscle invasive bladder cancer (MIBC) is an aggressive subtype of bladder cancer that invades the musculature of the bladder wall. Current standard treatment involves neoadjuvant chemotherapy followed by radical cystectomy, but MIBC carries a high risk of recurrence, with about half of patients...
Read MoreResearch Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung cancer (NSCLC), and current first-line standards based on immune checkpoint inhibitors (ICIs), with or without chemotherapy, yield suboptimal long-term outcomes. Olomorasib is an orally bioavailable, highly selective KRAS G12C inhibitor...
Read MoreResearch Summary: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies that frequently affect older adults and often require prolonged use of Bruton tyrosine kinase inhibitor (BTKi) therapy in the relapsed or refractory (R/R) setting. Ibrutinib and acalabrutinib are both recommended BTKis...
Read MoreResearch Summary: Capivasertib is a potent, selective inhibitor of all three protein kinase B (AKT1/2/3) isoforms. The phosphoinositide 3- kinase/protein kinase B pathway is frequently overactivated in many solid tumors, including hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) breast cancer. In the...
Read MoreResearch Summary: Covalent Bruton tyrosine kinase (BTK) inhibitors have become the preferred treatment for chronic lymphocytic leukemia (CLL). However, the first-generation BTK inhibitor ibrutinib, though effective, has been associated with cardiac toxicity, including atrial fibrillation, heart failure, and sudden death. Acalabrutinib, a second-generation, more selective...
Read MoreResearch Summary: Accurate prognostic assessment in patients with cutaneous melanoma is essential as it is one of the most prevalent malignancies in the United States. The American Joint Committee on Cancer (AJCC) staging system remains the cornerstone of risk stratification, but outcomes vary widely among...
Read More
Dr. Hagen Kennecke discusses the use of cabozantinib in the...
Read More
Nilo Azad, MD, a medical oncologist at Johns Hopkins, highlighted...
Read More
Dr. Vincent Xu discusses the safety and tolerability outcomes from...
Read More
Samantha Shenoy, MS, MSN, ACNP-BC, provides findings on the long-term...
Read More
Nayda Bidikian shared data from her oral abstract presentation, saying...
Read More
Romanos Sklavenitis-Pistofidis, MD, discusses that now that patients with smoldering...
Read More
Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, and Miriam Hobbs,...
Read More
Mary Steinbach, DNP, APRN, and Eliza Parkin, NP, discuss the...
Read More©2026 Oncology Matrix. All Rights Reserved.
